Early, real-world experience with direct oral anticoagulants in the treatment of intermediate-high risk acute pulmonary embolism | Zendy

Sónia Martins Santos | Zendy; Susana Cunha | Zendy; Rui Baptista | Zendy; Sílvia Monteiro | Zendy; Pedro Monteiro | Zendy; Francisco Gonçalves | Zendy; Mariano Pêgo | Zendy

Open Access

Early, real-world experience with direct oral anticoagulants in the treatment of intermediate-high risk acute pulmonary embolism

Author(s) -

Sónia Martins Santos,

Susana Cunha,

Rui Baptista,

Sílvia Monteiro,

Pedro Monteiro,

Francisco Gonçalves,

Mariano Pêgo

Publication year - 2017

Publication title -

revista portuguesa de cardiologia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.266

H-Index - 26

eISSN - 2174-2030

pISSN - 0870-2551

DOI - 10.1016/j.repc.2017.01.010

Subject(s) - medicine , pulmonary embolism , low molecular weight heparin , warfarin , cohort , retrospective cohort study , rivaroxaban , heparin , pulmonary artery , surgery , cardiology , atrial fibrillation

Intermediate-high risk pulmonary embolism (IHR-PE) has a poor prognosis, but is under-represented in trials of direct oral anticoagulants (DOACs) in venous thromboembolic disease (VTE). We aimed to assess whether the administration of DOACs was equivalent to the conventional (CONV) treatment of low-molecular weight heparin bridged with warfarin for treating IHR-PE.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research